KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1422-1426

  Paliogiannis, Panagiotis ^a   Cossu, Antonio ^a   Tanda, Francesco ^a   Palmieri, Giuseppe ^b   Palomba, Grazia ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b CNR   (Italy)

Author keywords

Colorectal cancer; KRAS gene; Mutation analysis

Indexed keywords

GENOMIC DNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CARCINOMA; EXON; EXON 2; EXON 3; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC CODE; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MUTATIONAL ANALYSIS; OMENTUM METASTASIS; ONCOGENE K RAS; PANCREAS METASTASIS; PATHOLOGY; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; VAGINA METASTASIS; VERY ELDERLY; WILD TYPE;

EID: 84923068071     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2411     Document Type: Article

References (42)

1. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
2. Palmieri G, Paliogiannis P, Scognamillo F, et al: Colorectal cancer epidemiology in an area with a spontaneous screening program. Acta Medica Mediterr 29: 231-234, 2013.
3. National Cancer Institute: Cancer Trends Progress Report-2011/2012 Update. http://progressreport.cancer.gov/doc_detail.asp?pid=1&did =2011&chid=105&coid=1026&mid=. Accessed December 5, 2013.
4. Yabroff KR, Mariotto AB, Feuer E and Brown ML: Projections of the costs associated with colorectal cancer care in the United States, 2000-2020. Health Econ 17: 947-959, 2008.
5. Edwards BK, Ward E, Kohler BA, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573, 2010.
6. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res 284: 31-53, 2003.
7. Yuan ZX, Wang XY, Qin QY, et al: The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8: e65995, 2013.
8. Malumbres M and Barbacid M: RAS Oncogenes: the first 30 years. Nat Rev Cancer 3: 459-485, 2003.
9. Heinemann V, Stintzing S, Kirchner T, Boeck S and Jung A: Clinical relevance of EGFR-and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35: 262-271, 2009.
10. Bardelli A and Siena S: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28: 1254-1261, 2010.
11. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
12. Markowitz SD and Bertagnolli MM: Molecular basis of colorectal cancer. N Engl J Med 361: 2404-2460, 2009.
13. Peltomäki P: Mutations and epimutations in the origin of cancer. Exp Cell Res 318: 299-310, 2012.
14. Boland CR and Goel A: Microsatellite instability in colorectal cancer. Gastroenterology 138: 2073-2087, 2010.
15. Jiang L, Huang M, Wang L, et al: Overexpression of MEKK2 is associated with colorectal carcinogenesis. Oncol Lett 6: 1333-1337, 2013.
16. Barzi A, Lenz AM, Labonte MJ and Lenz HJ: Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res 19: 5842-5848, 2013.
17. Vermaat JS, Nijman IJ, Koudijs MJ, et al: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res 18: 688-699, 2012.
18. Palomba G, Colombino M, Contu A, et al: Prevalence of KRAS, BRAF, and PIK3CAsomatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med 10: 178, 2012.
19. Ciavarella S, Milano A, Dammacco F and Silvestris F: Targeted therapies in cancer. BioDrugs 24: 77-88, 2010.
20. Winawer SJ: Natural history of colorectal cancer. Am J Med 106: 3S-6S, discussion, 50S-51S, 1999.
21. Swanton C: Intratumor heterogeneity: evolution through space and time. Cancer Res 72: 4875-4882, 2012.
22. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA and Cohen C: Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. Appl Immunohistochem Mol Morphol 18: 433-441, 2010.
23. Vignot S, Besse B, André F, Spano JP and Soria JC: Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 84: 301-313, 2012.
24. Shah SP, Morin RD, Khattra J, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813, 2009.
25. Ding L, Ellis MJ, Li S, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005, 2010.
26. Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113, 2010.
27. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117, 2010.
28. Goranova TE, Ohue M, Shimoharu Y and Kato K: Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis 28: 427-435, 2011.
29. Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862, 2009.
30. Knijn N, Mekenkamp LJ, Klomp M, et al: KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104: 1020-1026, 2011.
31. Cejas P, López-Gómez M, Aguayo C, et al: KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 4: e8199, 2009.
32. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13: 1270-1275, 2008.
33. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14: 4830-4835, 2008.
34. Park JH, Han SW, Oh DY, et al: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68: 1045-1055, 2011.
35. Watanabe T, Kobunai T, Yamamoto Y, et al: Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 54: 1170-1178, 2011.
36. Molinari F, Martin V, Saletti P, et al: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087-1094, 2009.
37. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27: 2622-2629, 2009.
38. Mariani P, Lae M, Degeorges A, et al: Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res 30: 4229-4235, 2010.
39. Baldus SE, Schaefer KL, Engers R, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799, 2010.
40. Italiano A, Hostein I, Soubeyran I, et al: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17: 1429-1434, 2010.
41. Han CB, Li F, Ma JT and Zou HW: Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest 30: 741-747, 2012.
42. Tolmachev V, Stone-Elander S and Orlova A: Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 11: 992-1000, 2010.